Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland

BACKGROUND: Increasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapene...

Descripción completa

Detalles Bibliográficos
Autores principales: Babouee Flury, Baharak, Bösch, Anja, Gisler, Valentin, Egli, Adrian, Seiffert, Salome N., Nolte, Oliver, Findlay, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166991/
https://www.ncbi.nlm.nih.gov/pubmed/37180441
http://dx.doi.org/10.3389/fcimb.2023.1098944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166991/
https://www.ncbi.nlm.nih.gov/pubmed/37180441
http://dx.doi.org/10.3389/fcimb.2023.1098944

Ejemplares similares